AR073800A1 - Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196 - Google Patents

Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196

Info

Publication number
AR073800A1
AR073800A1 ARP090103885A ARP090103885A AR073800A1 AR 073800 A1 AR073800 A1 AR 073800A1 AR P090103885 A ARP090103885 A AR P090103885A AR P090103885 A ARP090103885 A AR P090103885A AR 073800 A1 AR073800 A1 AR 073800A1
Authority
AR
Argentina
Prior art keywords
mirna
expression
hcv
bach
hmox1
Prior art date
Application number
ARP090103885A
Other languages
English (en)
Original Assignee
Charlotte Mecklenburg Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital
Publication of AR073800A1 publication Critical patent/AR073800A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud se refiere a métodos de tratamiento de células infectadas con VHC y de mamíferos que padecen la infeccion con el VHC mediante la transfeccion de las células infectadas con mímico miRNA-196. El mímico miRNA-196 disminuye significativamente la expresion de la proteína Bach 1 el gen del VHC, en tanto aumenta además la expresion del gen HMOX1. miRNA-196 se une al 3'-UTR del mRNA de Bach 1 para reducirla expresion de Bach 1. Como tal, el miRNA-196 puede jugar un papel importante en la regulacion de la replicacion del VHC y la expresion de HMOX1/Bach 1 en los hepatocitos. La presente solicitud además provee una formulacion para el tratamiento de células que expresan el VHC que comprende una cantidad terapéuticamente efectiva de miRNA-196 de modo que disminuya la expresion de Bach 1 y el gen del VHC incrementando a la par la expresion de HMOX1. Las formulaciones están adaptadas para permitir la transfeccion del mímico miRNA-196 en hepatocitos que expresan proteínas del VHC.
ARP090103885A 2008-10-08 2009-10-08 Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196 AR073800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10360908P 2008-10-08 2008-10-08

Publications (1)

Publication Number Publication Date
AR073800A1 true AR073800A1 (es) 2010-12-01

Family

ID=41559924

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103885A AR073800A1 (es) 2008-10-08 2009-10-08 Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196

Country Status (10)

Country Link
EP (1) EP2352829A1 (es)
JP (1) JP2012505233A (es)
KR (1) KR20110065568A (es)
CN (1) CN102257140A (es)
AR (1) AR073800A1 (es)
AU (1) AU2009302344A1 (es)
BR (1) BRPI0914060A2 (es)
CA (1) CA2739948A1 (es)
MX (1) MX2011003813A (es)
WO (1) WO2010042683A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN110724734B (zh) * 2019-10-22 2020-06-16 北京恩泽康泰生物科技有限公司 含miRNA mimic的人造脂质体及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US8415323B2 (en) * 2007-08-27 2013-04-09 The Regents Of The University Of California MicroRNAs for inhibiting viral replication

Also Published As

Publication number Publication date
KR20110065568A (ko) 2011-06-15
WO2010042683A1 (en) 2010-04-15
JP2012505233A (ja) 2012-03-01
CN102257140A (zh) 2011-11-23
EP2352829A1 (en) 2011-08-10
AU2009302344A2 (en) 2011-04-28
CA2739948A1 (en) 2010-04-15
MX2011003813A (es) 2011-07-28
BRPI0914060A2 (pt) 2015-11-17
AU2009302344A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
Qian et al. Exosomal microRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection
AR073800A1 (es) Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196
MX2020011805A (es) Agentes de iarn para infeccion causada por el virus de la hepatitis b.
CY1119765T1 (el) Ιοσωματιδια αδενο-συσχετιζομενου ιου με καψιδιο παραλλαγματος και μεθοδοι χρησης εξ' αυτων
Parashar et al. Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus
Li et al. Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis
Wen et al. Cellular microRNA-miR-548g-3p modulates the replication of dengue virus
BRPI0714495B8 (pt) lentivírus deficiente para replicação recombinante pseudotipado
Moschos et al. Cell-penetrating-peptide-mediated siRNA lung delivery
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
Han et al. Delivery of anti-miRNA-221 for colorectal carcinoma therapy using modified cord blood mesenchymal stem cells-derived exosomes
Hacke et al. Genetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity
Hansson et al. Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigmented epithelial cells
Park et al. Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L
Oh et al. Anti-viral activities of umbilical cord mesenchymal stem cell-derived small extracellular vesicles against human respiratory viruses
Chen et al. Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy
El Hidan et al. Scorpion‐Derived Antiviral Peptides with a Special Focus on Medically Important Viruses: An Update
Yang et al. Nesprin-1 plays an important role in the proliferation and apoptosis of mesenchymal stem cells
Chen et al. Ago-2-mediated slicer activity is essential for anti-flaviviral efficacy of RNAi
Elinger HBV: stowaway of NTCP
Porntrakulpipat et al. RNA interference targeting nucleocapsid protein (C) inhibits classical swine fever virus replication in SK-6 cells
Pan et al. Panax notoginseng saponins ameliorates coxsackievirus B3-induced myocarditis by activating the cystathionine-γ-lyase/hydrogen sulfide pathway
He et al. High reduced/oxidized glutathione ratio in infectious spleen and kidney necrosis virus-infected cells contributes to degradation of VP08R multimers
CN109971761B (zh) 脂肪酸结合蛋白4的小干扰rna及其应用
Ding et al. The program of antiviral agents inhibits virus infection

Legal Events

Date Code Title Description
FA Abandonment or withdrawal